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NIH/3T3Oncolytic viruses exploit alterations in cancer cells to speciﬁcally infect cancer cells but not normal healthy cells.
Previous work has shown that oncogenic Ras interferes with interferon (IFN) signaling to promote viral replica-
tion. Furthermore, inhibition of the Ras/Raf/MEK/ERK pathway at the level of Ras, MEK, or ERK was sufﬁcient to
restore IFN signaling. In order to identify genes that were commonly regulated by the inhibition of the Ras path-
way and the IFN pathway, we treated NIH/3T3 cells that overexpress oncogenic Ras with the MEK inhibitor,
U0126, or IFN-α for 6 h, and performed DNA microarray analysis (Gene Expression Omnibus accession number
GSE49469). Here, we also provide additional information on the experimental and functional analysis of the
genes responsive to U0126 and IFN.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).SpeciﬁcationsOrganism/cell line/tissue NIH/3T3 mouse embryonic ﬁbroblast cell line that
overexpresses human oncogenic H-Ras (RasV12)Sex n/a
Sequencer or array type Affymetrix Mouse Genome 430 2.0 DNA microarray
Data format Raw
Experimental factors Cells left treated with vehicle control (DMSO), U0126
(20 μM) or interferon (500 units/ml) for 6 h
Experimental features As above
Consent Raw data is free to use.
Sample source location n/aDirect link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49469
Experimental design, materials and methods
Cells and reagents
Murine ﬁbroblast cells (NIH/3T3) were obtained from the American
Type Culture Collection and maintained in high-glucose Dulbecco'sCanada, A1b 3X9. Tel.: +1 709
).
. This is an open access article undermodiﬁed Eagle's medium (Invitrogen, Burlington, Ontario, Canada)
with 10% fetal bovine serum (Cansera, Etobicoke, Ontario, Canada).
RasV12 cells were generated as previously described [1]. Recombinant
mouse IFN-α was purchased from PBL Interferon Source (Piscataway,
NJ) and U0126 from Cell Signaling Technology (Danvers, MA).RNA isolation
RNA was isolated from RasV12 cells treated with 20 μM U0126 or
500 units/ml IFN-α or treated with vehicle (DMSO) for 6 h. Total RNA
was isolated using TRIzol Reagent (Life Technologies, Ontario,
Canada), and then treated with DNase using TURBO DNA-free kit
(Ambion, Ontario, Canada). PCR analysis veriﬁed that the TURBO DNA-
free kit removed all detectable contaminating DNA.DNA microarray analysis
Isolated total RNAwas sent to the University Health Network (UHN)
microarray facility (Toronto, Canada) for analysis using Affymetrix 430
2.0mouse DNAmicroarrays. RNA quality was analyzedwith the Agilent
2100 Bioanalyzer (Agilent, Santa Clara, CA) by the UHN. RNA integrity
number was determined to be greater than 8.9 for all samples. Data
from three biological replicates were analyzed using GeneSpring (v7.3,
Agilent) and data was normalized to the median expression level of
each gene.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. Validation of gene expression change of 5 additional genes. A. RT–qPCR of Pycard,
Cd24a, BECN1, Gbp2b, and Irf7 was performed as previously described [2]. The relative
gene expression levels normalized to Gapdh and made relative to vehicle treated control
are shown. Mean ± sem, n = 3, *P b 0.05, and ***P b 0.01.
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Probesets with greater than 2.5 fold change compared to the vehicle
treated control were identiﬁed as being differentially expressed. A fold-
change cut-off strategy was used to reduce the type II (False negative)
error rate in order to identify all possible candidate genes. We identiﬁed
a total of 1883 probesets upregulated with MEK inhibition and 1877
probesets upregulated with IFN-α treatment (Fig. 1). Of these probesets,
619 were commonly upregulated by both MEK inhibition and IFN-α
treatment, and termed MEK-downregulated IFN-inducible (MDII) genes
[2]. Here we also report that 2184 probesets were downregulated by
U0126, 1656 probesetswere downregulated by IFN-α, and 424 probesets
were downregulated by both (Fig. 1).
Validation
The induction of nine genes representing genes identiﬁed by themi-
croarray as being upregulated by IFN-α alone, U0126 alone, or both IFN-
α and U0126 were validated by RT–qPCR, previously [2]. Using RT–
qPCR, the expression changes of 5 additional genes were determined
(Fig. 2), using the following forward (F) and reverse (R) primers:
BECN1 F: ACAAAAGCGCTCAAGTTCATGC, BECN1 R: GCAAACATCCCCTA
AGGAGCA, Cd24a F: ACTCAGGCCAGGAAACGTCTCT, Cd24a R: AACAGC
CAATTCGAGGTGGAC, Gbp2b F: CCGAGAAGCCAGAACATACC, Gbp2b R:
GAGGACTGCCAAAGCAAAGA, Pycard F: ACGGAGTGCTGGATGCTTT,
Pycard R: CTTGTCTTGGCTGGTGGTCT, Irf7 F: CCCAAGGAGAAGACCC
TGA, and Irf7 R: TAGACAAGCACAAGCCGAGA. Primers were validated
according to previously published strategies [3]. Statistically signiﬁcant
changes in log2-transformed relative expression levels were deter-
mined using 1-way ANOVA followed by Tukey HSD post-hoc analysis,
if signiﬁcant, in R v3 [4].
Themicroarray analysis identiﬁed Pycard and Cd24a to be upregulat-
ed by U0126 only, BECN1 (Beclin1) by both U0126 and IFN-α, as well as
Gbp2b (alias Gbp-1) and Irf7 by IFN-α only. The induction of Cd24a,
Gbp2b, and Irf7 was validated by RT–qPCR while changes to Pycard
and BECN1were not (Fig. 2). Of the three validated genes, the expres-
sion of Cd24a and Irf7 did not signiﬁcantly change by the combinedFig. 1. U0126 and IFN-α commonly upregulate 619 genes and downregulate 424 genes. A. Venn d
≥2.5-fold (bottom) by 6 h of U0126 or IFN-α treatment compared to vehicle control treated sam
level relative to the median expression level per gene.U0126 and IFN-α treatment. However, Gbp2b, showed increased induc-
tionwith the combined treatment. Subsequent analysis of the probesets
annotated for BECN1 revealed that these probesets also aligned to the
Cntd1 gene. Therefore, this gene was likely erroneously identiﬁed due
to the cross-reactivity of the microarray probeset.
Gene function analysis
Gene ontology analysis andnetwork analysis of genes thatwere either
upregulated or downregulated by both U0126 and IFN-α treatment were
analyzed by GeneMania [5]. To identify potential novel indirect interac-
tions, ten additional associated genes were added to the network by
GeneMania. Both upregulated anddownregulated lists generated a highly
networked set of genes based on co-expression, co-localization, physical
interactions, and shared protein domainswith only 1 gene not networked
in the upregulated list (Fig. 3A) and 6 genes not networked in the down-
regulated list (Fig. 3B).
Analysis of gene function revealed novel potential alterations to
signal transduction pathways and polysaccharide catabolism due toiagrams showing the number of probesets upregulated ≥2.5-fold (top) or downregulated
ple. B. Unsupervised hierarchical cluster of all genes from panel A indicating its expression
Fig. 3. Network analysis of genes commonly regulated by U0126 and IFN-α. A. Network analysis of 317 genes that were upregulated by U0126 and IFN-α and annotated by GeneMania. B.
Network analysis of 246 genes that were downregulated by U0126 and IFN-α and annotated by GeneMania. Black circles indicate genes identiﬁed by the microarray analysis and grey
circles identify genes added by GeneMania.
86 Y. Komatsu et al. / Genomics Data 4 (2015) 84–87downregulation of gene expression (Table 1). Additionally, there was
enrichment of genes involved in morphogenesis in the upregulated
gene list (Table 1). As a validation of this strategy to identify novel func-
tions of IFN-α and U0126 treatments, we also identiﬁed “response toTable 1
Functional enrichment of genes commonly regulated by U0126 and IFN-α.
Function Number of genes
In network In genome FDR
Upregulated genes (317 genes annotated)
Response to interferon-beta 8 28 b0.001
Cellular response to interferon-beta 7 23 b0.001
Intracellular region of host 5 10 0.001
Host cell cytoplasm part 5 10 0.001
Host intracellular part 5 10 0.001
Host cell cytoplasm 5 10 0.001
Host cell part 5 11 0.001
Extraorganismal space 5 14 0.002
Host 5 14 0.002
Host cell 5 14 0.002
Other organism 5 14 0.002
Other organism cell 5 14 0.002
Other organism part 5 14 0.002
Receptor complex 15 243 0.008
Epithelial tube morphogenesis 16 299 0.021
Defense response to protozoan 5 24 0.035
Response to protozoan 5 27 0.060
Respiratory system development 12 197 0.060
Lung development 11 172 0.076
Respiratory tube development 11 174 0.080
Downregulated genes (246 genes annotated)
Neurotransmitter receptor activity 7 49 0.04
Adenylate cyclase-modulating G-protein coupled
receptor signaling pathway
9 107 0.06
G-protein coupled receptor signaling pathway,
coupled to cyclic nucleotide second messenger
9 116 0.07
Phospholipase C-activating G-protein coupled
receptor signaling pathway
6 54 0.23
Regulation of B cell receptor signaling pathway 3 11 0.33
Neuropeptide receptor activity 4 24 0.33
Monocarboxylic acid transport 7 106 0.33
Stem cell proliferation 8 133 0.33
Mating behavior 4 27 0.33
Neuron projection terminus 7 105 0.33IFN” as signiﬁcantly enriched, which is a function known to be associat-
ed with IFN-α treatment and U0126 treatment [1,3,9,10].
Conclusion
The chosen method of analysis by fold-change resulted in the iden-
tiﬁcation of numerous novel genes upregulated and downregulated by
bothMEK inhibition and IFN-α treatment. As expected, we had a higher
type I error rate resulting in two genes that did not show the response
that was predicted by the microarray analysis. In addition to the genes
that were upregulated by U0126 and IFN-α treatment [2], we have
identiﬁed additional genes that are commonly downregulated by
these treatments. Analysis of gene networks revealed tight networks
suggesting that these genes are commonly regulated by other treat-
ments and/or in other cell types.
Functional analysis revealed additional functions of these gene sets
that could be analyzed in future investigations. The increase inmorpho-
genic gene changes aligns with recent evidence that infection of the
tumor vasculature by oncolytic viruses contributes to anti-tumor effects
[6,7]. Speciﬁcally, oncolytic Vesicular stomatitis virus (VSV) targets
tumor-speciﬁc vasculature in preference to normal vasculature [6]. Al-
though the mechanism underlying the tumor-speciﬁc targeting of the
vasculature by VSV has not yet been elucidated, the list of genes identi-
ﬁed with functions relating to morphogenesis includes genes involved
in vascular stability and remodeling, such as angiopoietin 1 (Angpt1),
and endothelial-speciﬁc receptor tyrosine kinase (Tek) [8]. Therefore,
it will be of interest to investigate whether destabilization of these
genes by oncogenic Ras is exploited by oncolytic viruses for tumor-
speciﬁc vascular disrupting effects.
Overall, we identiﬁed a signiﬁcant overlap of transcriptional activity
induced by oncogenic Ras/Raf/MEK/ERK inhibition and innate immune
response stimulated by type I IFN.
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